WO2024230734 - K-RAS INHIBITORS AND USE THEREOF
National phase entry is expected:
Publication Number
WO/2024/230734
Publication Date
14.11.2024
International Application No.
PCT/CN2024/091719
International Filing Date
08.05.2024
Title **
[English]
K-RAS INHIBITORS AND USE THEREOF
[French]
INHIBITEURS DE K-RAS ET LEUR UTILISATION
Applicants **
JACOBIO PHARMACEUTICALS CO., LTD.
Inventors
YANG, Hongwei
MA, Cunbo
GAO, Panliang
HAN, Huifeng
LI, Runze
WANG, Peng
WANG, Yanping
Priority Data
PCT/CN2023/097337
31.05.2023
CN
PCT/CN2023/092738
08.05.2023
CN
PCT/CN2023/094194
15.05.2023
CN
PCT/CN2023/093161
10.05.2023
CN
PCT/CN2023/093159
10.05.2023
CN
PCT/CN2023/092733
08.05.2023
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2423 | |
| EPO | Filing, Examination, Granting | 13950 | |
| Japan | Filing, Examination, Granting | 2041 | |
| South Korea | Filing, Examination, Granting | 1913 | |
| USA | Filing, Examination, Granting | 8790 |
Total:
29,117
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The invention relates to compounds that inhibit the activity of multiple forms of K-Ras protein including K-Ras wild type and K-Ras mutant types, compositions comprising the same, and the methods of using the same.[French]
L'invention concerne des composés qui inhibent l'activité de multiples formes de protéine K-Ras y compris des types sauvages de K-Ras et des types mutants de K-Ras, des compositions les comprenant, et leurs procédés d'utilisation.